Supernus Pharmaceuticals Inc
NASDAQ:SUPN

Watchlist Manager
Supernus Pharmaceuticals Inc Logo
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Watchlist
Price: 36.18 USD -4.21% Market Closed
Market Cap: 2B USD
Have any thoughts about
Supernus Pharmaceuticals Inc?
Write Note

Supernus Pharmaceuticals Inc
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Supernus Pharmaceuticals Inc
Cash Equivalents Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Cash Equivalents
$31.7m
CAGR 3-Years
-47%
CAGR 5-Years
-23%
CAGR 10-Years
-2%
Johnson & Johnson
NYSE:JNJ
Cash Equivalents
$4.8B
CAGR 3-Years
32%
CAGR 5-Years
27%
CAGR 10-Years
-10%
Bristol-Myers Squibb Co
NYSE:BMY
Cash Equivalents
$7.9B
CAGR 3-Years
-16%
CAGR 5-Years
-24%
CAGR 10-Years
5%
Pfizer Inc
NYSE:PFE
Cash Equivalents
$1.1B
CAGR 3-Years
-19%
CAGR 5-Years
-18%
CAGR 10-Years
-8%
Merck & Co Inc
NYSE:MRK
Cash Equivalents
$14.6B
CAGR 3-Years
13%
CAGR 5-Years
13%
CAGR 10-Years
3%
Eli Lilly and Co
NYSE:LLY
Cash Equivalents
$3.4B
CAGR 3-Years
-4%
CAGR 5-Years
17%
CAGR 10-Years
1%

See Also

What is Supernus Pharmaceuticals Inc's Cash Equivalents?
Cash Equivalents
31.7m USD

Based on the financial report for Sep 30, 2024, Supernus Pharmaceuticals Inc's Cash Equivalents amounts to 31.7m USD.

What is Supernus Pharmaceuticals Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
-2%

Over the last year, the Cash Equivalents growth was -67%. The average annual Cash Equivalents growth rates for Supernus Pharmaceuticals Inc have been -47% over the past three years , -23% over the past five years , and -2% over the past ten years .

Back to Top